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Summary nm23 gene expression has been shown to be inversely correlated with tumour metastatic potential
in some cancers but not in others. Examination was made of the expression of nm23-HI and nm23-H2 gene
products by immunohistochemistry and immunoblotting in 28 endomentrial carcinomas. Immunohistochemis-
try indicated the cytoplasm of cancer cells to be positive, and myometrium and endometrial stromal cells
negative, for nm23-Hl and -H2 protein. The staining intensity for these proteins was significantly stronger in
well-differentiated adenocarcinomas (GI) than in those moderately differentiated (G2) (P<0.05). nm23-HI
and -H2 proteins were shown by immunoblotting to be present at significantly higher levels in GI than in G2
tumours (P<0.05). Two of eight cases expressed high nm23-Hl and -H2 protein in poorly differentiated
adenocarcinomas (G3). In G3 tumours, nm23 expression may be diverse. In this study, the expression of
nm23-H1 and -H2 was not correlated with stage, metastasis, tumour size, myometrial invasion, oestrogen
receptor, progesterone receptor or menopause. It follows from the findings presented above that the high
expression of nm23-H1 and -H2 is positively correlated with histological differentiation.
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The nm23 gene has been shown to be a metastasis-suppressor
gene by differential hybridisation between two murine
melanoma sublines, one with high and the other with low
metastatic potential (Steeg et al., 1988). The deduced amino
acid sequence of the human nm23 gene shares 78%
homology with that of the Drosophila abnormal wing disc
(awd) gene (Rosengard et al., 1989). The gene product is
nucleoside diphosphate (NDP) kinase, which is essential for
maintaining nucleoside triphosphate (NTP) pools in cells
(Kimura et al., 1990; Wallet et al., 1990). There are two
isoforms of the human nm23 gene, nm23-H1 and nm23-H2
(Stahl et al., 1991). nm23-HI and nm23-H2 have been shown
to be identical respectively, to NDP kinases A and B from
human erythrocytes (Gilles et al., 1991).
The reduced expression of nm23 mRNA and protein is
associated with increased metastatic ability of human breast
carcinomas (Bevilacqua et al., 1989; Hennessy et al., 1991;
Hirayama et al., 1991; Royds et al., 1993). When the nm23
cDNA is transfected into a metastatic murine melanoma cell
line expressing low levels of this particular gene, transfected
clones expressing the exogeneously induced nm23 gene show
significantly reduced in vivo metastatic potential (Leone et al.,
1991). However, studies on colon carcinoma or neuroblas-
toma indicate increased nm23 gene expression to be
associated with advanced stages of the disease (Hailat et al.,
1991; Leone et al., 1993; Myeroff and Markowitz, 1993).
Correlations between nm23 expression and metastatic poten-
tial would thus appear to depend on specific cancers.
Endometrial carcinoma is the most prevalent neoplasm of
the female pelvis and has been detected in patients under the
age of 45 (Jeffery et al., 1987). There is no report on the
expression of nm23 in endometrial carcinoma. Thus, in this
study, examination was made of the expression of nm23-HI
and nm23-H2 in endometrial carcinomas by immunohis-
tochemical and immunoblotting methods to clarify the
association of nm23 expression with tumour metastatic
potential, degree ofdifferentiation, clinical stage, tumour size,
myometrial invasion, oestrogen receptor (ER), progesterone
receptor (PR) and menopause.
Materials and methods
Tissue samples
Thirty primary uterine malignant tumour specimens were
surgically obtained from the pathology files of Kitasato
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University Hospital between 1992 and 1993. Assessment of
clinical stage and the degree of differentiation was conducted
according to the new classification of the International
Federation of Gynecology and Obstetrics (FIGO, 1989).
There were 15 well-differentiated (GI), five moderately
differentiated (G2) and eight poorly differentiated adenocar-
cinomas (G3) and two leiomyosarcomas of the uterine cor-
pus. Patient age ranged from 36 to 80 years, the median
being 57 years. ER and PR in tumour tissue freshly obtained
at surgery were measured by the radioreceptor assay system
of Kitasato Biochemical Laboratory, Kanagawa, Japan. A
tissue sample (0.5 cm3) was also obtained and processed by
AMeX, as described below.
AMeXprocedure
Sato et al. (1986, 1992) devised the AMeX (acetone,
methylbenzoate, xylene) procedure for tissue processing and
paraffin embedding before haematoxylin-eosin staining,
immunostaining and immunoblotting. Morphological preser-
vation of sections prepared by this method is consistently
better than that of frozen sections and similar to that of
routinely formalin-fixed paraffin sections. Proteins extracted
from AMeX-processed tissue can be applied to immunoblot-
ting. The technique is very simple for general clinical
laboratory use, and paraffin blocks fixed by this method can
be stored at 4C for future study. Immunohistochemistry and
immunoblotting were performed on the specimens obtained
from the same block.
Immunohistochemistry
Two mouse monoclonal antibodies (MAb), H1-229 (MAb for
nm23-HI) and H2-439 (MAb for nm23-H2), were kindly
provided by Dr Shiku, Department of Oncology, Nagasaki
University, Nagasaki, Japan (Urano et al., 1993). Paraffin-
embedded samples were sectioned at 4 ytm and deparaffinised
with Histo-Clear (National Diagnostics, Atlanta, GA, USA).
They were then immediately immersed in 4% parafor-
maldehyde for 5 min and washed with phosphate-buffered
saline (PBS 0.0075 M pH 7.4). Immunohistochemical staining
was carried out by the avidin-biotin-peroxidase complex
(ABC) method. In brief, the sections were incubated with 2%
normal swine serum and then with H1-229 (2 tgml-') or
H2-439 (4pgml-') overnight at room temperature, rinsed
with PBS and incubated with biotinylated anti-mouse IgG
(200-fold diluted, Vector, Burlingame, CA, USA) for 30 min.
This was followed by reaction in 0.3% hydrogen peroxide in
methanol for 30min and then ABC and diaminobenzidinenm23 expression in endometrial carcinoma
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reactions. Nuclear counterstaining was done using Mayer's
haematoxylin solution. As negative controls, sections were
stained by replacing the primary antibody with normal
mouse serum at the same IgG concentration. Immunostain-
ing intensity was categorized as strongly positive (+ +),
positive (+) or negative (-) in comparison with background
intensity.
Immunoblotting
Sections of cancer area were selectively cut from AMeX-
processed tissue. They were deparaffinised with xylene and
washed by centrifugation in acetone. All specimens were
resuspended in Laemmli's sample buffer (Laemmli, 1970) by
brief sonication and diluted to 4 mg protein ml-'. Lysates of
10 LI (40 jig of protein) were heated at 100°C for 3 min and
loaded onto a 15% SDS-polyacrylamide gel, which was then
transferred to a nylon membrane (Immobilon-P, Millipore).
The membrane was incubated with Block Ace (Dainihon
Seiyaku, Suita, Osaka, Japan) and then with H1-229
(2 jigml-') or H2-439 (2 g m-1) for h, rinsed with PBS
containing 0.3% Tween (PBS-T). This was followed by
incubation with peroxidase-labelled anti-mouse IgG (1000-
fold diluted, Dako, Kyoto, Japan) for 1 h. A band was
detected on exposed X-ray film by a Western blot
chemiluminescence reagent (DuPont, Boston, MA, USA).
Densitometric scanning was performed with a CS 9000 den-
sitometer (Shimazu, Kyoto, Japan) at 550 nm. The data were
normalised as relative rates based on nm23 gene product
content in the lysate (1 fig of protein) of the mouse myeloma
cell line NS-1 transfected with either the nm23-H gene
(NS-HI-9) or nm23-H2 gene (NS-H2-1) (Urano et al., 1993)
in the same membrane. NS-H1-9 and NS-H2-1 were also
provided by Dr Shiku, Department of Oncology, Nagasaki
University. Relative immunoblotting values were classed as 0,
-; 0-0.8, +; over 0.8, + +; and were compared with those
for immunostaining.
Statistical analysis was conducted by the Mann-Whitney
U-test. P-values less than 0.05 were considered significant.
Results
Immunohistochemical analysis ofnm23-HJ and -H2protein
The cytoplasm of cancer cells was stained diffusely with
H1-229 (nm23-Hl) and H2-439 (nm23-H2). There was no
different staining pattern between the central area and the
leading invasive edge of the tumour. Endometrial stromal
cells showed negligible staining (Figure 1). The relationship
between tumour differentiation and expression of nm23-H
and -H2 protein as determined by immunohistochemical
staining is shown in Table I. The staining intensity of nm23-
H1 and -H2 was significantly stronger in GI than in G2
(P<0.05) and stronger in GI than in G3. No correlation
could be found between the staining intensity of GI and G3,
since there were two strongly positive cases in eight G3
tumours. Nor was there any association of the immunoreac-
tivity of nm23-Hl and -H2 with any other clinicopathological
parameter (data not shown).
Two uterine leiomyosarcomas stained positively with MAb
nm23-H1 and -H2. Two myometrial and two uterine cervical
tissue specimens failed to stain by either MAb. Negative
control sections were not stained.
Immunoblotting analysis ofnm23-HJ and -H2 protein
Examples of nm23-H and -H2 protein expression of NS-H 1-
9 and NS-H2-4 cell lysates as positive controls and five
endometrial carcinomas are shown in Figure 2. MAb H1-229
and H2-439 detected specific bands of 20.5 kDa (nm23-H1)
and 18 kDa (nm23-H2) protein respectively.
Though the detection of nm23 gene products by immunos-
taining was possible, immunoblotting analysis could not be
b
Figure 1 Immunohistochemical staining strongly positive for (a) nm23-HI and (b) nm23-H2 protein in the cytoplasm of
well-differentiated endometrial adenocarinoma. (c) Positive staining for nm23-HI protein and (d) negative staining for nm23-H2
protein in poorly differentiated endometrial adenocarcinoma. (ABC method, counterstained with haematoxylin, bar = 50 im.)
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Table I Immunohistochemical results for nm23-HI and nm23-H2 gene products in relation to
histological differentiation
Intensity of immunostaining
nm23-HJ nm23-H2
Histology No. of cases - + + + P-value - + + + P-value
15
5
8
0 6
4
5
9
0
2
<0.05*
0
0
5
5
5
101
2
<0.05*
Leiomyosarcoma 2 0 2 0 0 2 0
Myometrium 2 2 0 0 2 0 0
Uterine cervix 2 2 0 0 2 0 0
G1, well-differentiated adenocarcinoma; G2, moderately differentiated adenocarcinoma; G3,
poorly differentiated adenocarcinoma; -, negative; +, positive; + +, strongly positive;
*P<0.05, significant (Mann-Whitney U-test).
20.5 kDa _
Lane
Value 1.0 0.6 0.1 0.4 0.5 0.3
D
l8 kDa -ap
Lane H2 1 2 3 4 5
Value 1.0 0.9 0.1 1.1 0.4 0.9
Figure 2 Identification by immunoblotting analysis of (a)
20.5 kDa protein (nm23-H1) in lane HI corresponding to the
NS-HI-9 myeloma cell line transfected with nm23-HI gene and
five endometrial carcinomas (lanes 1-5) using MAb H1-229 and
(b) 18 kDa protein (nm23-H2) in lane H2 corresponding to the
NS-H2-I myeloma cell line transfected with nm23-H2 gene and
five endometrial carcinomas (lanes 1-5), using MAb H2-439.
Values of densitometric analysis were normalised based on those
in lanes HI and H2.
conducted in two cases of G1, in one case because more than
half the tissue had almost completely degenerated and in the
other case because there was only a small portion of cancer
area in the tissue. The relation between the expression of
nm23-H1 and -H2 protein as determined by immunoblotting
and clinicopathological data is shown in Table II.
Mean relative values of tumour nm23-H1 and -H2 protein
in comparison with the positive controls, i.e. NS-HI-9 and
NS-H2-1 cell lysates, were 0.7 ± 0.4 and 0.7 ± 0.5 in GI,
0.2 ± 0.2 and 0.2 ± 0.2 in G2 and 0.6 ± 0.4 and 0.5 ± 0.4 in
G3. The values for nm23-H1 and -H2 were significantly
higher in GI than in G2 (P<0.05). No correlation was
apparent between the values for nm23-H1 and -H2 in GI
and in G3 since there were two out of eight G3 tumour cases
with high values of these parameters. The values for nm23-
HI and -H2 in two leiomyosarcomas were 0.1 and 1.2, and
0.1 and 0.1 respectively. Two myometrial and two uterine
cervical tissue specimens showed no expression of nm23-H1
or -H2 protein.
Comparison ofnm23-HJ and -H2protein expression
determined by immunohistochemical and immunoblotting
analysis
Agreement rates of data obtained by immunohistochemical
and immunoblotting analysis for nm23-HI and -H2 protein
expression were 69% (22/32) and 66% (21/32) respectively.
Rates were higher by immunohistochemical analysis than by
immunoblotting analysis were in 19% (6/32) and 25% (8/32)
respectively. Rates were lower by immunohistochemical
analysis than by immunoblotting analysis in 12% (4/32) and
9% (3/32) respectively.
Correlation ofnm23-HJ and -H2protein expression based on
immunoblotting and clinicopathological data
The expression of nm23-H and -H2 showed no relation to
stage, metastasis, tumour size, myometrial invasion, ER, PR
or menopause in endometrical carcinoma by immunoblotting
analysis (Table II).
Discussion
In this study, assessment was made of the expression of
nm23-H and nm23-H2 protein in endometrial carcinomas
processed by the AMeX method (Sato et al., 1986, 1992), in
conjunction with immunohistochemical staining and
immunoblotting. Agreement rates of the estimation of nm23-
HI and -H2 protein expression by immunostaining and
immunoblotting were 69% and 66%. In disagreement cases,
immunohistochemical analysis tended to be estimated as
higher than immunoblotting, possibly owing to subjective
estimation in immunostaining. It thus follows that it is more
accurate to determine the localisation of nm23 protein
expression by immunostaining and nm23 protein levels by
immunoblotting.
No correlation could be detected between the expression of
nm23-Hl and -H2 protein and putative prognostic factors
such as stage, metastatic potential, tumour size, myometrial
invasion, ER, PR and menopause. The reduced expression of
nm23 mRNA and protein is associated with increased metas-
tatic potential in human breast (Bevilacqua et al., 1989;
Hennessy et al., 1991; Hirayama et al., 1991; Royds et al.,
1993), hepatocellular (Nakayama et al., 1992), gastric car-
cinomas (Nakayama et al., 1993) and malignant melanoma
(Fl0renes et al., 1992). Increased nm23 expression has been
shown to be associated with advanced stages of colon car-
cinoma (Myeroff and Markowitz, 1993) and neuroblastoma
(Hailat et al., 1991; Leone et al., 1993). No relationship
between nm23 protein expression and clinicopathological fac-
tors has been demonstrated in breast (Sastre-Garau et al.,
1992; Sawan et al., 1994) and pulmonary carcinoma
(Higashiyama et al., 1992). nm23-, (analogous to human
nm23-H 1) and nm23-a (analogous to human nm23-H2) exp-
ression differs according to the organ in rat (Kimura et al.,
1990; Shimada et al., 1993). The transfection of nm23 cDNA
into a high metastatic K-1735 TK murine melanoma cell line
significantly reduces in vivo metastatic potential (Leone et al.,
1991), but heterogeneity in nm23 expression among K-1735
clones and hybrids produced by the fusion of non-metastatic
and metastatic K-1735 is not correlated with metastatic
capability (Radinsky et al., 1992). It would thus appear that
GI
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17
1471
anm23expression inendometrialcarcinoma
J Watanabe etal
1 A79
Table II Correlation between nm23-HI and nm23-H2 protein expression by immunoblotting and
clinicopatholo6ical parameters in patients with endometrial carcinoma
Clinicopathological nm23-HI nm23-H2
parameters No. of cases Mean value ± 5.d.a P-value Mean value + s.d.a P-value
Histological grade
GI 13 0.7 0.4 P<0.05 0.7 0.5 }P <0.5*
G2 5 0.2±0.2 J0.2±0.2j
G3 8 0.6±0.4 0.5±0.4
Stage
I A, B, C 13 0.6±0.5 0.5±0.5
II A, B 4 0.3 0.1 NS 0.4 0.4 NS
III A,B,C and IVA,B 9 0.7 0.4 0.6 0.5
Metastasis
+ 7 0.6±0.4 NS 0.5±0.5 NS
19 0.5±0.4 0.5±0.4
Tumour size
<5cm 12 0.6±0.5 NS 0.5±0.5 NS
>5cm 14 0.5±0.3 0.5 0.4
Myometrial invasion
4 0.6 ± 0.5 0.6 ± 0.6
<1/2 12 0.6±0.5 NS 0.5±0.5 NS
>1/2 10 0.6±0.4 0.6±0.4
ER
+ 15 0.5±0.4 NS 0.5±0.4 NS
6 0.7 0.4 0.6 0.5
PR
+ 13 0.6±0.5 NS 0.5 0.5 NS
8 0.5±0.3 0.4 0.4
Menopause
Pre 7 0.5±0.4 NS 0.5 0.5 NS
Post 19 0.6 0.4 0.5 0.4
aValue, relative value of tumour nm23-H1 and nm23-H2 protein based on positive controls, i.e. NS-H1-9
and NS-H2-1 cell lines. *P<0.05, significant (Mann-Whitney U-test); NS, not significant. GI,
well-differentiated adenocarcinoma; G2, moderately differentiated adenocarcinoma; G3, poorly differentiated
adenocarcinoma; Stage, new FIGO classification. ER, oestrogen receptor; PR, progesterone receptor; +,
positive; -, negative; pre, premenopause; post, post-menopause.
any metastatic enhancer/suppressor function of nm23 may be
tumour specific and/or the mechanism for nm23 expression
may differ according to biochemical conditions.
The intensity of immunostaining of nm23-H1 and -H2 was
significantly stronger in GI than in G2 (P<0.05). nm23-HI
and -H2 protein were present significantly (P<0.05) more in
GI than in G2 according to immunoblotting analysis. Strong
and weak intensity in G3 was apparent by immunostaining.
The high content of nm23-Hl and -H2 protein would thus
appear associated with the high degree of differentiation of
endometrial carcinomas, while there may be two types of
poorly differentiated endometrial adenocarcinomas.
Confirmation of this will require study on a greater number
of cases. nm23 mRNA and protein are expressed more in
well-differentiated tumours of human breast cancer (Hen-
nessy et al., 1991; Royds et al., 1993). Intense immunostain-
ing of nm23-HI in human prostate cancer has been detected
more often in poorly differentiated than moderately
differentiated types (Igawa et al., 1994). The tissue- and
developmental phase-specific expression of nm23 gene (awd
gene) in Drosophila has been observed (Timmons et al.,
1993). The expression of nm23 may depend on primary sites
and their differentiation.
nm23-H2 protein has been identified as the human c-myc
transcription factor PuF, thus showing a relationship
between nm23-H2 and c-myc oncogene expression and sug-
gesting nm23-H2 protein to be essential to transcriptional
activation of the c-myc gene (Postel et al., 1993). The inverse
relation between c-myc expression and cell differentiation is
well documented (Spencer and Groudine, 1991) and nm23
has been shown to inhibit the differentiation of mouse
myeloid leukaemia cells (Okabe-Kado et al., 1992). The
elevated expression of nm23 is associated with N-myc
amplification in advanced stages of human neuroblastomas
(Hailat et al., 1991; Leone et al., 1993). The mechanism for
nm23 expression in well-differentiated tumours is still un-
known. Poorly differentiated endometrial carcinomas highly
expressing nm23-H2 may be independent of oestrogens and
associated with c-myc overexpression.
In future study, clarification should be made of qualitative
and quantitative relations between nm23-H2 and c-myc exp-
ression in endometrial carcinomas. It should also be deter-
mined whether nm23-H1 and -H2 have specific roles in
tumour differentiation and if there are actually two types of
endometrial carcinomas which express nm23 protein to
different degrees.
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